The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.
https://www.pharmalive.com/wp-content/uploads/2023/09/antibody-molecule.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-08 08:55:192023-09-08 08:55:57Seagen, Nurix team to create new class of antibody conjugates for cancer
